EPHA2 biallelic disruption causes syndromic complex microphthalmia with iris hypoplasia.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 06 04 2022
revised: 26 06 2022
accepted: 20 07 2022
pubmed: 3 8 2022
medline: 16 9 2022
entrez: 2 8 2022
Statut: ppublish

Résumé

Disruption of any of the ocular development steps can result in ocular defects such as microphthalmia, coloboma and anterior segment dysgeneses including aniridia and cataract. All of these anomalies can be isolated or seen in association with each other. Except for aniridia (almost exclusively due to PAX6 mutations), most of these congenital ocular malformations are related to a wide genetic heterogeneity, as hundreds of genes are implied in ocular development. Here we describe a patient presenting with bilateral microphthalmia, congenital cataract, corneal dystrophy and iris hypoplasia, associated with extra-ocular features, who underwent an analysis of 119 ocular development related genes. Genetic testing revealed the presence of two truncating variants in the EPHA2 gene. While EPHA2 mutations are mainly known to be responsible for isolated dominant congenital cataract, we report here the first case of complex anterior segment dysgenesis caused by a biallelic EPHA2 mutation. This gene should be screened in case of aniridia with a negative PAX6 testing, as the ocular features of our patient clearly mimic those of PAX6 mutated patients. This observation enlarges the phenotype associated with EPHA2 variations and rise the insight of a possible PAX6-EPHA2 interaction that needs further investigations. Moreover, despite a great variability in ocular and extra-ocular phenotypes, mutations type and inheritance pattern, a possible genotype-phenotype correlation can also be drawn for this gene.

Identifiants

pubmed: 35918037
pii: S1769-7212(22)00155-0
doi: 10.1016/j.ejmg.2022.104574
pii:
doi:

Substances chimiques

Eye Proteins 0
Homeodomain Proteins 0
PAX6 Transcription Factor 0
Paired Box Transcription Factors 0
Repressor Proteins 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104574

Informations de copyright

Copyright © 2022. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest Authors declared no conflict of interest.

Auteurs

Cécile Courdier (C)

Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, France; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, France.

Anna Gemahling (A)

Service d'ophtalmologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.

Damien Guindolet (D)

Service d'ophtalmologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.

Amandine Barjol (A)

Service d'ophtalmologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.

Claire Scaramouche (C)

Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, France.

Laurence Bouneau (L)

Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, France.

Patrick Calvas (P)

Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, France; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, France.

Gilles Martin (G)

Service d'ophtalmologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.

Nicolas Chassaing (N)

Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, France; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, France.

Julie Plaisancié (J)

Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, France; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, France; Unité Inserm 1214 ToNIC, Hôpital Purpan, Toulouse, France. Electronic address: plaisancie.j@chu-toulouse.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH